3h (edited) • 📚 Peptides 101
🧬 CAGRILINTIDE: WHAT IS IT?
Cagrilintide keeps showing up next to semaglutide in weight-loss news. Here's what it actually is.
WHAT IT IS
• A long-acting, lab-made version of amylin, a hormone your pancreas releases alongside insulin after you eat
• Built to last much longer in the body than natural amylin or the older amylin drug pramlintide
• Developed by Novo Nordisk, the company behind semaglutide
HOW IT WORKS
• Amylin is a fullness signal: it slows how fast the stomach empties and tells the brain you've eaten
• Cagrilintide hits amylin receptors and related calcitonin receptors
• It works on a different pathway than GLP-1 drugs, which is why researchers pair the two
WHAT THE RESEARCH LOOKS AT
• Phase 2 trial in adults with obesity (Lancet 2021): up to about 11% average weight loss over 26 weeks vs about 3% on placebo
• CagriSema, cagrilintide plus semaglutide, in the phase 3 REDEFINE 1 trial (NEJM 2025): about 20% average weight loss over 68 weeks vs about 3% on placebo
• The most common side effects were stomach-related, like nausea and constipation
Evidence level: Moderate to strong in human trials, mostly as part of CagriSema.
Exact dosing and timing are in the Premium classroom.
For research use only, not medical advice.
Takeaway: cagrilintide is the amylin half of CagriSema, a second fullness signal that researchers are stacking on top of GLP-1s.
0
0 comments
🧬 CAGRILINTIDE: WHAT IS IT?
skool.com/peptideindex
Free peptide education plus 20+ vetted, lab-tested vendors. Don't just trust your source, verify it.
Leaderboard (30-day)
1
+14
2
+13
3
+9
4
+2
5
+2
Powered by